{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:04:04Z","timestamp":1783602244959,"version":"3.55.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1038\/s41582-023-00803-4","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T11:02:40Z","timestamp":1680519760000},"page":"329-330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Zavegepant for the acute treatment of migraine: look before leaping"],"prefix":"10.1038","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6268-727X","authenticated-orcid":false,"given":"H\u00e5kan","family":"Ashina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peer","family":"Tfelt-Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,3]]},"reference":[{"key":"803_CR1","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"M Ashina","year":"2020","unstructured":"Ashina, M. Migraine. N. Engl. J. Med. 383, 1866\u20131876 (2020).","journal-title":"N. Engl. J. Med."},{"key":"803_CR2","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","volume":"17","author":"AK Eigenbrodt","year":"2021","unstructured":"Eigenbrodt, A. K. et al. Diagnosis and management of migraine in ten steps. Nat. Rev. Neurol. 17, 501\u2013514 (2021).","journal-title":"Nat. Rev. Neurol."},{"issue":"Suppl. 1","key":"803_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1046\/j.1526-4610.2002.0420s1003.x","volume":"42","author":"RB Lipton","year":"2002","unstructured":"Lipton, R. B., Hamelsky, S. W. & Dayno, J. M. What do patients with migraine want from acute migraine treatment? Headache 42 (Suppl. 1), 3\u20139 (2002).","journal-title":"Headache"},{"key":"803_CR4","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/S0140-6736(20)32342-4","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina, M. et al. Migraine: integrated approaches to clinical management and emerging treatments. Lancet 397, 1505\u20131518 (2021).","journal-title":"Lancet"},{"key":"803_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","volume":"397","author":"R Croop","year":"2021","unstructured":"Croop, R. et al. Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial. Lancet 397, 51\u201360 (2021).","journal-title":"Lancet"},{"key":"803_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1474-4422(22)00517-8","volume":"22","author":"RB Lipton","year":"2023","unstructured":"Lipton, R. B. et al. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol. 22, 209\u2013217 (2023).","journal-title":"Lancet Neurol."},{"key":"803_CR7","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/head.14389","volume":"62","author":"R Croop","year":"2022","unstructured":"Croop, R. et al. Zavegepant nasal spray for the acute treatment of migraine: a phase 2\/3 double-blind, randomized, placebo-controlled, dose-ranging trial. Headache 62, 1153\u20131163 (2022).","journal-title":"Headache"},{"key":"803_CR8","doi-asserted-by":"crossref","unstructured":"Derry, S. & Moore, R. A. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst. Rev. 2013, CD008040 (2013).","DOI":"10.1002\/14651858.CD008614.pub2"},{"key":"803_CR9","doi-asserted-by":"crossref","unstructured":"Derry, C. J., Derry, S. & Moore, R. A. Sumatriptan (all routes of administration) for acute migraine attacks in adults \u2014 overview of Cochrane reviews. Cochrane Database Syst. Rev. 2014, CD009108 (2014).","DOI":"10.1002\/14651858.CD009108.pub2"},{"key":"803_CR10","doi-asserted-by":"crossref","unstructured":"Bird, S., Derry, S. & Moore, R. A. Zolmitriptan for acute migraine attacks in adults. Cochrane Database Syst. Rev. 2014, CD008616 (2014).","DOI":"10.1002\/14651858.CD008616.pub2"}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-023-00803-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-023-00803-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-023-00803-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T11:10:27Z","timestamp":1685963427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-023-00803-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,3]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["803"],"URL":"https:\/\/doi.org\/10.1038\/s41582-023-00803-4","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,3]]},"assertion":[{"value":"3 April 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.A. reports personal fees from Teva, outside of the submitted work. P.T.-H. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}